A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Agouron Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Cytomegalovirus Retinitis; HIV Infections

Treatments: Drug: Nelfinavir mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002169

259A

Study 517

AG1343-517

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.

Sex: All

Ages: 13+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV infection.
• Newly diagnosed or first progression of CMV retinitis.

Exclusion Criteria

Prior Medication:

Excluded:

Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.